Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05859932 | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05858203 | Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment(AATF/Che-1) | unknown | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05855460 | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | unknown | — | 20 | Cairo UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05252403 | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL | unknown | Phase 2 | 35 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05840289 | A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma(FRILLY) | unknown | — | 94 | University Hospital, GenevaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05834751 | the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma | unknown | N/A | 144 | Ou Bai, MD/PHDOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05832125 | Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia(ALLTARGETOBS) | unknown | — | 80 | Versailles HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04139252 | A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients(HO902DLBCL) | unknown | — | 250 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04957693 | Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period | unknown | N/A | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05823701 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | unknown | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05749133 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | XuYanOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05821192 | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. | unknown | N/A | 34 | Ou Bai, MD/PHDOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05822037 | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 6 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04271410 | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04271800 | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04648475 | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04649983 | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04782193 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04861480 | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05490953 | Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma | unknown | Phase 4 | 30 | University of GuadalajaraOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03510767 | A Study of TQ-B3525 on Tolerance and Pharmacokinetics | unknown | Phase 1 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05438394 | Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM | unknown | Phase 1 | 24 | Peking University People's HospitalOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05811910 | Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL | unknown | — | 290 | IRCCS Burlo GarofoloOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05308225 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 72 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809167 | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT | unknown | Phase 2 | 55 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05802992 | The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | unknown | Phase 3 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05797948 | GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | unknown | N/A | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05793463 | Anti-mullerian Hormone in Acute Lymphoblastic Leukemia | unknown | — | 10 | IRCCS Burlo GarofoloOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT01593488 | Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children(CILI) | unknown | Phase 2 | 31 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05772000 | Clinical Significance of Occult Central Nervous System Localization | unknown | — | 70 | University of Rome Tor VergataOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05776407 | Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 12 | Chongqing University Cancer HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | unknown | Phase 3 | 116 | Air Force Military Medical University, ChinaOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | unknown | — | 150 | Maastricht University Medical CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05772728 | Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | unknown | N/A | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2023source: clinicaltrials